Author:
Funck-Brentano Thomas,Vanjak Arnaud,Ostertag Agnes,Nethander Maria,Fernandez Sylvie,Collet Corinne,Hans Didier,van Rietbergen Bert,Cohen-Solal Martine
Reference29 articles.
1. A clinician’s guide to X-linked hypophosphatemia;Carpenter;J. Bone Miner. Res.,2011
2. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia;Carpenter;J. Clin. Investig.,2014
3. Burosumab therapy in children with X-linked hypophosphatemia;Carpenter;N. Engl. J. Med.,2018
4. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis;Insogna;J. Bone Miner. Res.,2018
5. Asia-Pacific consensus recommendations on X-linked hypophosphatemia: diagnosis, multidisciplinary management, and transition from pediatric to adult care;Munns;JBMR Plus,2023